(with much hope this group does not sell their patent to Amgen....)

http://www.ncbi.nlm.nih.gov/pubmed/1...?dopt=Abstract

1: Int J Pharm. 2009 Oct 10. [Epub ahead of print]Related Articles, Links
Production of highly pure human glycosylated GDNF in a mammalian cell-line.

Ansorena E, Garbayo E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ.

Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, C/Irunlarrea 1, E-31080 Pamplona, Spain.

The administration of glial cell line-derived neurotrophic factor (GDNF) has emerged as a promising strategy for the treatment of several diseases of the nervous system as Parkinson's disease, amyotrophic lateral sclerosis, spinal cord injury and nerve regeneration as well as ocular diseases and drug addictions. A procedure for the purification of human recombinant glycosylated GDNF using a mammalian expression system as the source of the protein is discussed in the present paper. The neurotrophic factor was purified using cation exchange chromatography and gel filtration. A human cell line was chosen as the source of therapeutic protein, since a recombinant protein with a structure and glycosylation pattern equivalent to the native form is desirable for its prospective therapeutic utilization. The activity of the highly pure protein obtained was confirmed with a cell based bioassay. The purified protein is suitable for its in vivo evaluation in animals and for possible subsequent clinical application.

PMID: 19825405 [PubMed - as supplied by publisher]